Advertisement

Eligibility for PCSK-9 inhibitors treatment in acute coronary syndrome, chronic coronary artery disease and outpatient dyslipidemic patients

      Highlights

      • Eligibility for proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors.
      • Adjustable predictive model software.
      • Coronary artery disease patients.
      • Familial hypercholesterolaemia patients.

      Abstract

      Background and aims

      We aimed to investigate potential eligibility for proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors in patients with coronary artery disease and dyslipidaemia according to patient characteristics and variable criteria.

      Methods

      We prospectively enrolled 2000 patients (acute coronary syndrome = 407, chronic coronary artery disease inpatients = 1087, outpatient Lipid's clinic = 506). To calculate PCSK-9 inhibitors real-world eligibility, a proprietary adjustable software was developed, which stores data and patient characteristics and can determine eligibility depending on different criteria. We tested four scenarios with different LDL thresholds according to ESC/EAS 2016 and 2019 Guidelines, 2017 American College of Cardiology Expert Consensus, and National criteria.

      Results

      The eligible percentage was 18.85%, 9.75%, 8.55% and 2.15%, in the total population for the four classifications, respectively, and it varied according to clinical status. The increase toward more recent guidelines was mostly attributed to the increasing number of coronary patients who become eligible as our criteria become stricter.

      Conclusions

      For the first time, a realistic estimation of PCSK-9 eligibility is provided via an adjustable predictive model in a population of 2000 patients with acute coronary syndrome, chronic coronary artery disease and dyslipidaemia. This can be a valuable tool for the incorporation of PCSK-9 inhibitors in health care systems.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ference B.A.
        • Ginsberg H.N.
        • Graham I.
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur. Heart J. 2017; 38: 2459-2472https://doi.org/10.1093/eurheartj/ehx144
        • Baigent C.
        • Blackwell L.
        • Emberson J.
        • Holland L.E.
        • Reith C.
        • Blaha N.
        • Peto R.
        • Barnes E.H.
        • Keech A.
        • Simes J.
        • Collins R.
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681https://doi.org/10.1016/S0140-6736(10)61350-5
        • Cannon C.P.
        • Blazing M.A.
        • Giugliano R.P.
        • McCagg A.
        • White J.A.
        • Theroux P.
        • Darius H.
        • Lewis B.S.
        • Ophuis T.O.
        • Jukema J.W.
        • De Ferrari G.M.
        • Ruzyllo W.
        • De Lucca P.
        • Im K.
        • Bohula E.A.
        • Reist C.
        • Wiviott S.D.
        • Tershakovec A.M.
        • Musliner T.A.
        • Braunwald E.
        • Califf R.M.
        • IMPROVE-IT Investigators
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N. Engl. J. Med. 2015; 372: 2387-2397https://doi.org/10.1056/NEJMoa1410489
        • Katsiki N.
        • Mikhailidis D.P.
        • Banach M.
        Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
        Expet Opin. Pharmacother. 2019 Nov; 20: 2007-2017https://doi.org/10.1080/14656566.2019.1649394.Epub2019Aug6
        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • Ginsberg H.N.
        • Masana L.
        • Descamps O.S.
        • Wiklund O.
        • Hegele R.A.
        • Raal F.J.
        • Defesche J.C.
        • Wiegman A.
        • Santos R.D.
        • Watts G.F.
        • Parhofer K.G.
        • Hovingh G.K.
        • Kovanen P.T.
        • Boileau C.
        • Averna M.
        • Borén J.
        • Bruckert E.
        • Catapano A.L.
        • Kuivenhoven J.A.
        • Pajukanta P.
        • Ray K.
        • Stalenhoef A.F.
        • Stroes E.
        • Taskinen M.R.
        • TybjærgHansen A.
        • European Atherosclerosis Society Consensus Panel
        Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.
        Eur. Heart J. 2013; 34: 3478https://doi.org/10.1093/eurheartj/eht273
        • Pećin I.
        • Hartgers M.L.
        • Hovingh G.K.
        • Dent R.
        • Reiner Ž.
        Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors.
        Eur. J. Prev. Cardiol. 2017 Sep; 24: 1383-1401https://doi.org/10.1177/2047487317717346.Epub2017Jun23
        • Šimić I.
        • Reiner Ž.
        Adverse effects of statins - myths and reality.
        Curr. Pharmaceut. Des. 2015; 21: 1220-1226
        • Vlachopoulos C.
        • Kosteria I.
        • Sakka S.
        • Gkourogianni A.
        • Terentes-Printzios D.
        • Koutagiar I.
        • Skoumas I.
        • Miliou A.
        • Papassotiriou I.
        • Gardikioti V.
        • Loutradis D.
        • Chrousos G.
        • Kanaka-Gantenbein C.
        • Tousoulis D.
        PCSK9 and Lp(a) levels of children born after assisted reproduction technologies.
        J. Assist. Reprod. Genet. 2019 Jun; 36 (Epub 2019 May 11): 1091-1099https://doi.org/10.1007/s10815-019-01474-1
        • Cohen J.C.
        • Boerwinkle E.
        • Mosley Jr., T.H.
        • Hobbs H.H.
        Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
        Nav. Eng. J. Med. 2006; 354: 1264-1272
        • Stein E.A.
        • Mellis S.
        • Yancopoulos G.D.
        • Stahl N.
        • Logan D.
        • Smith W.B.
        • Lisbon E.
        • Gutierrez M.
        • Webb C.
        • Wu R.
        • Du Y.
        • Kranz T.
        • Gasparino E.
        • Swergold G.D.
        Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
        N. Engl. J. Med. 2012; 366: 1108-1118https://doi.org/10.1056/NEJMoa1105803
        • Raal F.J.
        • Stein E.A.
        • Dufour R.
        • Turner T.
        • Civeira F.
        • Burgess L.
        • Langslet G.
        • Scott R.
        • Olsson A.G.
        • Sullivan D.
        • Hovingh G.K.
        • Cariou B.
        • Gouni-Berthold I.
        • Somaratne R.
        • Bridges I.
        • Scott R.
        • Wasserman S.M.
        • Gaudet D.
        • Rutherford-2 Investigators
        PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2014; 385: 331-340https://doi.org/10.1016/S0140-6736(14)61399-4
        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • Honarpour N.
        • Wiviott S.D.
        • Murphy S.A.
        • Kuder J.F.
        • Wang H.
        • Liu T.
        • Wasserman S.M.
        • Sever P.S.
        • Pedersen T.R.
        FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N. Engl. J. Med. 2017; 376: 1713-1722https://doi.org/10.1056/NEJMoa1615664
        • Schwartz G.G.
        • Bessac L.
        • Berdan L.G.
        • Bhatt D.L.
        • Bittner V.
        • Diaz R.
        • Goodman S.G.
        • Hanotin C.
        • Harrington R.A.
        • Jukema J.W.
        • Mahaffey K.W.
        • Moryusef A.
        • Pordy R.
        • Roe M.T.
        • Rorick T.
        • Sasiela W.J.
        • Shirodaria C.
        • Szarek M.
        • Tamby J.F.
        • Tricoci P.
        • White H.
        • Zeiher A.
        • Steg P.G.
        Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
        Am. Heart J. 2014; 168: 682-689https://doi.org/10.1016/j.ahj.2014.07.028.e1
        • Reiner Ž.
        PCSK9 inhibitors in clinical practice: expectations and reality.
        Atherosclerosis. 2018 Mar; 270 (Epub 2018 Jan 31): 187-188https://doi.org/10.1016/j.atherosclerosis.2018.01.001
        • Mach F.
        • Baigent C.
        • Catapano A.L.
        • Koskinas K.C.
        • Casula M.
        • Badimon L.
        • Chapman M.J.
        • De Backer G.
        • Ference B.A.
        • Graham I.A.
        • Halliday A.
        • Landmesser U.
        • Mihaylova B.
        • Pedersen T.R.
        • Riccardi G.
        • Richter D.J.
        • Sabatine M.
        • Taskinen M.R.
        • Tokgozoglu L.
        • Wiklund O.
        ESC/EAS Guidelines for the Management of Dyslipidaemias:lipid Modification to Reduce Cardiovascular Risk.
        (Netherlands)2019
        • Catapano A.L.
        • Graham I.
        • De Backer G.
        • Wiklund O.
        • Chapman M.J.
        • Drexel H.
        • Hoes A.W.
        • Jennings C.S.
        • Landmesser U.
        • Pedersen T.R.
        • Reiner Z.
        • Riccardi G.
        • Taskinen M.R.
        • TokgozogluL
        • Verschuren W.M.M.
        • Vlachopoulos C.
        • Wood D.A.
        • Zamorano J.L.
        ESC/EAS Guidelines for the Management of Dyslipidaemias.
        2016
        • Kolovou G.D.
        • Watts G.F.
        • Mikhailidis D.P.
        • Pérez-Martínez P.
        • Mora S.
        • Bilianou H.
        • Panotopoulos G.
        • Katsiki N.
        • Ooi T.C.
        • Lopez-Miranda J.
        • Tybjærg-Hansen A.
        • Tentolouris N.
        • Nordestgaard B.G.
        Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profiles: executive summary of a 2019 Expert panel statement.
        Curr. Vasc. Pharmacol. 2019; 17: 538-540https://doi.org/10.2174/1570161117999190517115432
        • Law M.R.
        • Wald N.J.
        • Rudnicka A.R.
        Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
        BMJ. 2003; 326: 1423-1427
        • Davidson M.H.
        • Ballantyne C.M.
        • Kerzner B.
        • Melani L.
        • Sager P.T.
        • Lipka L.
        • Strony J.
        • Suresh R.
        • Veltri E.
        Efficacy and safety of ezetimibe co-administered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia.
        Int. J. Clin. Pract. 2004; 58: 746-755
        • Bruckert E.
        • Degennes J.L.
        • Baigts F.
        • Malbecq W.
        Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
        Clin. Cardiol. 1995; 629: 621-629
        • Lloyd-Jones D.M.
        • Morris P.B.
        • Ballantyne C.M.
        • Birtcher K.K.
        • Daly Jr., D.D.
        • DePalma S.M.
        • Minissian M.B.
        • Orringer C.E.
        • Smith Jr., S.C.
        Focused update of the 2016 ACC Expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on Expert consensus decision pathways.
        J. Am. Coll. Cardiol. 2017; 70 (2017 Oct 3): 1785-1822https://doi.org/10.1016/j.jacc.2017.07.745.Epub2017Sep5
        • Ministry of Health
        Scientific Working Group of Cardiovascular Disease.
        Dyslipidaemia, March 2018
        • Vlachopoulos C.
        • Koutagiar I.
        • Skoumas I.
        • Terentes-Printzios D.
        • Zacharis E.
        • Kolovou G.
        • Stamatelopoulos K.
        • Rallidis L.
        • Katsiki N.
        • Bilianou H.
        • Liberopoulos E.
        • Miliou A.
        • Kafouris P.
        • Georgakopoulos A.
        • Gardikioti V.
        • Tousoulis D.
        • Anagnostopoulos C.
        Long-Term administration of proprotein convertase subtilisin/kexin type 9 inhibitors reduces arterial FDG uptake.
        JACC (J. Am. Coll. Cardiol.): Cardiovasc. Imag. 2019 Dec 2019; 12: 2571-2578
      1. Rallidis LS, Skoumas I, Liberopoulos EN, Vlachopoulos C, Kiouri E, Koutagiar I, Anastasiou G, Kosmas N, Elisaf MS, Tousoulis D, Iliodromitis E. PCSK9 inhibitors in clinical practice: novel directions and new experiences, Hellenic J. Cardiol., https://doi.org/10.1016/j.hjc.2019.10.003.

        • Kazi D.S.
        • Penko J.
        • Coxson P.G.
        • Moran A.E.
        • Ollendorf D.A.
        • Tice J.A.
        • Bibbins-Domingo K.
        Updated Cost-effectiveness analysis of PCSK9 Inhibitors Based on the results of the FOURIER trial.
        J. Am. Med. Assoc. 2017 Aug 22; 318: 748-750https://doi.org/10.1001/jama.2017.9924
        • Myers K.D.
        • Farboodi N.
        • Mwamburi M.
        • Howard W.
        • Staszak D.
        • Gidding S.
        • Baum S.J.
        • Wilemon K.
        • Rader D.J.
        Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes.
        Circ. Cardiovasc. Qual. Outcomes. 2019 Aug; 12e005404https://doi.org/10.1161/CIRCOUTCOMES.118.005404.Epub2019Jul23
        • Gencer B.
        • Koskinas K.C.
        • Räber L.
        • Karagiannis A.
        • Nanchen D.
        • Auer R.
        • Carballo D.
        • Carballo S.
        • Klingenberg R.
        • Heg D.
        • Matter C.M.
        • Lüscher T.F.
        • Rodondi N.
        • Mach F.
        • Windecker S.
        Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European society of Cardiology/European atherosclerosis society (ESC/EAS) guidelines after acute coronary syndromes.
        Am. Heart J. Assoc. 2017 Nov 9; 6e006537https://doi.org/10.1161/JAHA.117.006537
        • Butty A.
        • Gencer B.
        • Koskinas K.C.
        • Carballo D.
        • Räber L.
        • Klingenberg L.
        • Matter C.M.
        • Lüscher T.F.
        • Windecker S.
        • Muller O.
        • Rodondi N.
        • Mach F.
        • Nanchen D.
        Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors.
        Int. J. Cardiol. 2019 Oct 7; https://doi.org/10.1016/j.ijcard.2019.10.012
        • Hess P.L.
        • Kennedy K.
        • Cowherd M.
        • Virani S.S.
        • Masoudi F.A.
        • Navar A.M.
        • Yeh R.W.
        • Ho P.M.
        • Maddox T.M.
        Implications of the FDA approval of PCSK9inhibitors and FOURIER results for contemporary cardiovascular practice: an NCDR Research to Practice(R2P) project.
        Am. Heart J. 2018 Jan; 195 (Epub 2017 Sep. 9): 151-152https://doi.org/10.1016/j.ahj.2017.09.004
        • Rallidis L.S.
        • Lekakis J.
        PCSK9 inhibition as an emerging lipid lowering therapy: unanswered questions.
        Hellenic J. Cardiol. 2016; 57: 86e91
        • Bacquer D.
        • Smedt D.
        • Reiner Ž.
        • Tokgözoğlu L.
        • Clays E.
        • Kotseva K.
        • Rydén L.
        • Wood D.
        • Backer G.
        Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: real world evidence from clinical practice: data from the ESC-EORP EUROASPIRE V Study.
        Eur. J. Prev. Cardiol. 2019 Sep 9; (2047487319874898)https://doi.org/10.1177/2047487319874898
        • Krysa J.A.
        • Ooi T.C.
        • Proctor S.D.
        • Vine D.
        Nutritional and lipid modulation of PCSK9: effects on cardiometabolic risk factors.
        J. Nutr. 2017 Apr; 147 (Epub 2017 Feb 8): 473-481https://doi.org/10.3945/jn.116.235069
        • Chernogubova E.
        • Strawbridge R.
        • Mahdessian H.
        • Mälarstig A.
        • Krapivner S.
        • Gigante B.
        • Hellénius M.L.
        • de Faire U.
        • Franco-Cereceda A.
        • Syvänen A.C.
        • Troutt J.S.
        • Konrad R.J.
        • Eriksson P.
        • Hamsten A.
        • van 't Hooft F.M.
        Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.
        Arterioscler. Thromb. Vasc. Biol. 2012 Jun; 32 (Epub 2012 Mar 29): 1526-1534https://doi.org/10.1161/ATVBAHA.111.240549